In the United States, a stroke occurs every 40 seconds, frequently with devastating results. Timely access to care remains a substantial barrier despite advancements in therapy, especially outside of urban regions.
With an inventive solution, Miami firm NAVIGANTIS is stepping forward to meet this need. The firm is well-positioned to realize its objective of revolutionizing neurovascular treatment with its VASCO robotic platform, since it just secured a $12 million Series A financing round.
The funding, which is being led by Puma Venture Capital and includes participation from Cormorant Asset Management and Mirae Asset Capital, will support the VASCO robot’s continued development and testing, advancing it closer to clinical trials involving humans.
In the United States, a stroke occurs every 40 seconds, frequently with devastating results. Timely access to care remains a substantial barrier despite advancements in therapy, especially outside of urban regions.
With an inventive solution, Miami firm NAVIGANTIS is stepping forward to meet this need. The firm is well-positioned to realize its objective of revolutionizing neurovascular treatment with its VASCO robotic platform, since it just secured a $12 million Series A financing round.
The funding, which is being led by Puma Venture Capital and includes participation from Cormorant Asset Management and Mirae Asset Capital, will support the VASCO robot’s continued development and testing, advancing it closer to clinical trials involving humans.
CEO of NAVIGANTIS Mor Dayan emphasized the company’s joy and thankfulness for the support of prestigious investors while highlighting their common goal of transforming neurovascular treatment. “We are thrilled and fortunate to have the support of such esteemed partner investors who share our vision for revolutionizing neurovascular care with robotics,” the statement read.
One of the main causes of impairment is neurological illnesses. The gold standard for treating acute ischemic stroke is now a mechanical thrombectomy; yet, timely access to this potentially life-saving operation is still scarce. Many patients miss the critical window for treatment, which significantly lowers their chances of recovery. This is due to the existing dearth of qualified neurointerventionalists and the geographic limitations of care centers.
Puma Venture Capital founder and managing partner Amit Hazan expressed his excitement about the potential impact of the VASCO platform. Hazan will now be a member of the NAVIGANTIS Board of Directors. He declared, “We are incredibly excited to support the NAVIGANTIS team in their mission to further improve stroke care via robotic applications,”
Hazan outlined the wider ramifications of this technique, which include the ability to do telesurgery and the development of novel vascular treatments including drug delivery and brain implants. Prior to this, Hazan oversaw the medical technology division of Goldman Sachs as a Managing Director.
Major businesses in the medical technology sector, including Opko Health and Medtronic, are building substantial regional presences, and South Florida is fast becoming as a center for these technologies.
Puma Venture Capital founder and managing partner Amit Hazan expressed his excitement about the potential impact of the VASCO platform. Hazan will now be a member of the NAVIGANTIS Board of Directors. He declared, “We are incredibly excited to support the NAVIGANTIS team in their mission to further improve stroke care via robotic applications,”
Hazan outlined the wider ramifications of this technique, which include the ability to do telesurgery and the development of novel vascular treatments including drug delivery and brain implants. Prior to this, Hazan oversaw the medical technology division of Goldman Sachs as a Managing Director.
The money raised will play a crucial role in advancing the VASCO robot toward its first-in-human clinical trials, a significant advancement in the care of neurovascular diseases. NAVIGANTIS seeks to close the gap in neurovascular care by increasing patient access to cutting-edge therapies, wherever they may be.
Puma Venture Capital, which was founded in 2023 by Amit Hazan and Dr. Vipul Patel, is committed to promoting minimally invasive care by making strategic investments in robotics, digital surgery, AI analytics, diagnostics, medicines, and digital ecosystems. Patel, who received his degree from the University of Michigan, is currently the Medical Director of the Florida Hospital Cancer Institute for Urologic Oncology and the Global Robotics Institute. He also teaches urology at the University of Central Florida.
